Vaccines,antibodies,therapeutic proteins,Influenza vaccines| iBio, Inc.

Vaccines, antibodies and therapeutic proteins are currently produced in bacteria and yeast (microbes), in mammalian and insect cell culture and in transgenic animals.

Influenza vaccines are produced in millions of fertilized chicken eggs, taking up to six months, which makes it difficult to react to mutating virus strains and limits the amount that can be produced each flu season.

The iBioLaunch™ platform has significant advantages over current production methods, and over systems being developed in transgenic plants:

System	Overall Cost	Production Timescale	Scale-up Capacity	Product Quality	Glycosylation	Contamination Risks	Storage Costs
Microbial	Low - Medium	Short - Medium	High	Low - Medium	None or Incorrect	Endotoxins	Moderate
Cell culture	High	Long	Very low	Very high	Correct	Viruses, prions, oncogenic DNA	Expensive
Transgenic animals	High	Very long	Low	Very high	Correct	Viruses, prions, oncogenic DNA	Expensive
Transgenic plants	Very low	Long	Very high	High	Minor differences	Low risk	Inexpensive
iBioLaunch™ in plants	Very low	Short	Very high	High	Minor differences	Low risk	Inexpensive

Source: Ma et al. (2003) Nature Reviews Genetics 4:794-805.